PDF(Pubmed)
Abstract：
The subspecialty of cardio-oncology aims to reduce cardiovascular morbidity and mortality in patients with cancer or following cancer treatment. Cancer therapy can lead to a variety of cardiovascular complications, including left ventricular systolic dysfunction, pericardial disease, and valvular heart disease. Echocardiography is a key diagnostic imaging tool in the diagnosis and surveillance for many of these complications. The baseline assessment and subsequent surveillance of patients undergoing treatment with anthracyclines and/or human epidermal growth factor (EGF) receptor (HER) 2-positive targeted treatment (e.g. trastuzumab and pertuzumab) form a significant proportion of cardio-oncology patients undergoing echocardiography. This guideline from the British Society of Echocardiography and British Cardio-Oncology Society outlines a protocol for baseline and surveillance echocardiography of patients undergoing treatment with anthracyclines and/or trastuzumab. The methodology for acquisition of images and the advantages and disadvantages of techniques are discussed. Echocardiographic definitions for considering cancer therapeutics-related cardiac dysfunction are also presented.
摘要：
心脏肿瘤学的亚专业旨在降低癌症患者或癌症治疗后的心血管发病率和死亡率。癌症治疗可导致多种心血管并发症,包括左心室收缩功能障碍,心包疾病,和心脏瓣膜病.超声心动图是诊断和监测许多此类并发症的关键诊断成像工具。接受蒽环类和/或人表皮生长因子(EGF)受体(HER)2阳性靶向治疗(例如曲妥珠单抗和帕妥珠单抗)治疗的患者的基线评估和随后监测形成了接受超声心动图的心脏肿瘤患者的显著比例。英国超声心动图学会和英国心血管肿瘤学会的指南概述了接受蒽环类和/或曲妥珠单抗治疗的患者的基线和监测超声心动图方案。讨论了获取图像的方法以及技术的优缺点。还介绍了考虑癌症治疗相关心脏功能障碍的超声心动图定义。
